Skip to main content

Table 3 Baseline features of the participants

From: Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis

Studies Age (years) Males (%) Duration of DM (years) HbA1c (%) HBP (%) CS (%)
  DP/NDP DP/NDP DP/NDP DP/NDP DP/NDP DP/NDP
Gantz2017 63.7/63.6 69.6/70.7 12.0/12.1 8.00/8.00 95.1/95.6 14.3/14.5
Green2015
Park2015 61.0/63.0 66.2/62.2 7.60/7.20 79.7/80.4
Scirica2013 65.1/65.0 66.6/67.3 10.3/10.3 8.00/8.00 81.2/82.4
Shih2016 74.5/74.5 46.2/46.2 8.70/8.70 90.9/90.9
Wang2015 66.0/65.9 64.0/63.7 75.1/75.9
White2013 61.0/61.0 67.7/68.0 7.10/7.30 8.00/8.00 82.5/83.6 13.0/14.3
  1. Abbreviations: DM Diabetes mellitus, HbA1c Glycated hemoglobin, HBP High blood pressure, CS Current smoker, DP Dipeptidyl peptidase 4 inhibitor group, NDP Non-dipeptidyl peptidase 4 inhibitor group